Company / Working Capital
Corvus Pharmaceuticals, Inc. Working Capital History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$19.0M
FY2024
5-year range
$19.0M / $61.6M
FY2020-FY2024
Trend
-9.9%
vs FY2023
Sector context
#208 of 215
Health Care
What the data says
Among 215 Health Care companies, Corvus Pharmaceuticals, Inc. is in the bottom 3% for working capital. Working Capital has declined for 3 consecutive years, from $62M in FY2021 to $19M in FY2024.
Based on SEC 10-K filings.
$19M in FY2024 with a 5-year CAGR of -22.8%.
Declined from $33M to $19M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -32.4%
- 5-Year CAGR
- -22.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 3% in Health CareTop 97% of 215This company $19.0M Sector average $957.8M
▼
-98.0% below sector average
Key checks
Key Insights
- Corvus Pharmaceuticals, Inc.'s working capital has declined for 3 consecutive years.
- 5-year CAGR of -22.8%, indicating a declining trend.
- In FY2024, working capital decreased 9.9% year-over-year.
- Ranks #208 out of 215 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $19.0M | -9.9% |
| FY2023 | $21.1M | -35.9% |
| FY2022 | $32.9M | -46.6% |
| FY2021 | $61.6M | +85.7% |
| FY2020 | $33.2M | -52.0% |
| FY2019 | $69.1M | -36.3% |
| FY2018 | $108.6M | +32.0% |
| FY2017 | $82.3M | -36.8% |
| FY2016 | $130.1M | +40.5% |
| FY2015 | $92.6M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026